The Maryland Prescription Drug Affordability Board agreed to set an higher fee restrict for the Ozempic diabetes therapy, marking the second time that the state panel has taken such a step in current weeks.
The board, which is designed to operate like a state utility fee, will now oversee a course of to decrease the price of the sort 2 diabetes drugs for the state and native governments by January 2027. On the time, the worth will probably be capped at $274 for a 30-day provide, a transfer the board estimates will save $5.8 million a 12 months.
The anticipated value was benchmarked in opposition to the utmost truthful worth paid by Medicare, stated Andrew York, govt director of the Maryland board. In the meantime, the board is predicted to start appearing in 2028 to set higher fee limits on high-cost medication bought by all Marylanders within the business insurance coverage market as nicely.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
View All Plans